ability to obtain coverage and payment
from health plans and payers for diagnostic and therapeutic products
applying Rosetta's technology and Rosetta's short operating history; as
well as those risks more fully discussed under "Key Information - Risk
Factors" in Rosetta's Annual Report on Form 20-F for the year ended
December 31, 2006 on file with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Rosetta's views only as
of today and should not be relied upon as representing its views as of any
subsequent date. Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
ROSETTA GENOMICS LTD. AND ITS SUBSIDIARY
(A development stage company)
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
March 31, December 31,
2008 2007
Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 9,511 $ 13,590
Short-term bank deposits 114 112
Marketable securities 8,964 8,251
Other accounts receivable and prepaid
expenses 405 297
Total current assets 18,994 22,250
LONG-TERM INVESTMENTS 2,089 2,391
SEVERANCE PAY FUND 171 144
PROPERTY AND EQUIPMENT, NET 1,340 1,253
Total assets $ 22,594 $ 26,038
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT L
'/>"/>
SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Related biology technology :1.
Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 20072.
NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma3.
Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference4.
Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference5.
Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 20076.
Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 20077.
Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer8.
Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology9.
Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma10.
Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 200811.
Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer